LifeSci Capital Initiates Coverage of GeNeuro S.A.

Lead Candidate GNbAc1 Targets the potential underlying cause of Multiple Sclerosis; Report Available here: www.lifescicapital.com/equity-research/geneuro/

NEW YORK, NY / ACCESSWIRE / August 31, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of GeNeuro (Euronext Paris: GNRO.PA), a Swiss company developing treatments for autoimmune conditions caused by the pathogenic expression of human endogenous retroviral (HERV) genetic elements.

GeNeuro’s lead candidate is GNbAc1, a monoclonal antibody against the envelope protein of the multiple sclerosis associated retrovirus (MSRV-Env). MSRV-Env is a HERV element that is silent in healthy people but ubiquitously expressed in multiple sclerosis (MS) lesions. MSRV-Env has been shown to activate the toll-like receptor 4 (TLR4) pathway, a component of the innate immune system, and has been proposed as a causal trigger to the neuroinflammation and neurodegeneration seen in MS. GNbAC1 may prevent the immune activation thought to set the disease process in motion, reflecting a novel treatment strategy that could be highly disruptive to the MS treatment landscape. GeNeuro is currently evaluating GNbAC1 in a Phase IIb study with funding from their partner Servier and expects to report preliminary results in the fourth quarter of 2017.

The existing scientific literature suggests that a drug with anti-HERV activity may be effective in many autoimmune conditions in addition to MS, such as chronic inflammatory demyelinating polyneuropathy (CIDP) and type 1 diabetes (T1D). GeNeuro’s anti-HERV platform and expertise in HERV-mediated disease could allow for GeNeuro to develop disruptive therapies for these indications. The Company also has a preclinical candidate against HERV-K that is in development for amyotrophic lateral sclerosis (ALS).

In a 36 page Initiation Report, LifeSci Capital explains the Company’s novel treatment strategy for MS, the potential complications with existing therapies resulting from broad suppression of the immune system, and the large market opportunity for disease-modifying MS therapies.

Dr. Sherman’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on GeNeuro as developments occur.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

David Sherman, Ph.D.
Phone: (212) 915-2570
Email: dsherman@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 444609